Dr. Alinari is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
400 W 12th Ave
481a Wiseman Hall
Columbus, OH 43210Phone+1 614-366-3802Fax+1 614-293-7526- Is this information wrong?
Education & Training
Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2013 - 2016- Ohio State University HospitalResidency, Internal Medicine, 2011 - 2013
University of BolognaPhD, Experimental Therapeutics for Hematologic Malignancies, 2008 - 2011
University of Florence Faculty of MedicineClass of 1998
Certifications & Licensure
OH State Medical License 2011 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Clinical Trials
- Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Start of enrollment: 2016 Dec 20
- A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma Start of enrollment: 2019 Oct 15
Roles: Principal Investigator
- Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma Start of enrollment: 2023 Mar 06
Roles: Contact, Sponsor-Investigator, Principal Investigator
Publications & Presentations
PubMed
- Post-infusion PD-1+CD8+CAR-T cells identify patients responsive to CD19-CAR-T therapy in non-Hodgkin's lymphoma.Nathan Denlinger, No-Joon Song, Xiaoli Zhang, Hyeongseon Jeon, Chelsea Peterson, Yi Wang, Kelsi Reynolds, Robert Bolz, Jessica Miao, Chunhua Song, Dayong Wu, Wing Keun...> ;Blood Advances. 2024 Mar 23
- Resistance to PRMT5-targeted therapy in mantle cell lymphoma.Mackenzie Elizabeth Long, Shirsha Koirala, Shelby Sloan, Fiona Brown-Burke, Christoph Weigel, Lynda Villagomez, Kara Corps, Archisha Sharma, Ian Hout, Margaret Harper,...> ;Blood Advances. 2024 Jan 9
- 2 citationsA novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models.Wing Keung Chan, Jessica Williams, Kinnari Sorathia, Betsy Pray, Kaled Abusaleh, Zehua Bian, Archisha Sharma, Ian Hout, Shamama Nishat, Walter Hanel, Shelby L Sloan, A...> ;Experimental Hematology & Oncology. 2023 Sep 22
- Join now to see all
Abstracts/Posters
- Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of...Lapo Alinari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- PRMT5 Inhibition Drives Therapeutic Vulnerability to BCL-2 Inhibition with Venetoclax and Provides Rationale for Combination Therapy in Mantle Cell LymphomaLapo Alinari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- A Phase I Study of Nivolumab and Lenalidomide in Relapsed/ Refractory B Cell LymphomaLapo Alinari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Press Mentions
Recipients of AACR Research Funding & Fellowships 1993–2017September 8th, 2017
Hospital Affiliations
The OSUCCC - JamesColumbus, Ohio
Ohio State University Wexner Medical CenterColumbus, Ohio
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
